TABLE 1.
The results of gene-based analysis for gastric cancer.
| Gene | Chr | OR (95% CI) | p-value | Method |
|---|---|---|---|---|
| KRTCAP2 | 1q22 | 0.65 (0.60–0.71) | 8.44E-24 | Burden Test |
| MUC1 | 1q22 | 0.76 (0.71–0.81) | 1.99E-14 | Meta |
| MTX1 | 1q22 | 0.71 (0.63–0.80) | 1.70E-08 | Burden Test |
| GBAP1 | 1q22 | 0.48 (0.42–0.55) | 1.03E-27 | Burden Test |
| EFNA1 | 1q22 | 0.82 (0.77–0.87) | 1.46E-10 | Meta |
| TRIM46 | 1q22 | 0.71 (0.66–0.76) | 1.65E-21 | Burden Test |
| THBS3 | 1q22 | 0.51 (0.45–0.57) | 6.39E-29 | Burden Test |
| HCN3 | 1q22 | 0.83 (0.80–0.87) | 2.65E-17 | Meta |
| DAP3P1 | 1q22 | 0.64 (0.56–0.74) | 1.56E-10 | Meta |
| MST O 1 | 1q22 | 0.67 (0.60–0.75) | 1.60E-12 | Meta |
| DAP3 | 1q22 | 0.65 (0.58–0.73) | 4.23E-13 | Meta |
| GON4L | 1q22 | 0.63 (0.55–0.72) | 4.47E-11 | Meta |
| RPL7P10 | 1p31.1 | 1.25 (1.10–1.42) | 5.76E-04 | Meta |
| SERINC2 | 1p35.2 | 1.01 (0.96–1.06) | 8.05E-01 | Meta |
| RMDN2 | 2p22.2 | 0.67 (0.58–0.78) | 3.24E-07 | Meta |
| LYPD6 | 2q23.2 | 0.84 (0.77–0.91) | 4.27E-05 | Meta |
| BAZ2B | 2q24.2 | 1.29 (1.14–1.45) | 2.59E-05 | Meta |
| BZW1 | 2q33.1 | 0.97 (0.93–1.01) | 1.56E-01 | Meta |
| UMPS | 3q21.2 | 1.03 (0.99–1.08) | 2.00E-01 | Meta |
| ITGB5 | 3q21.2 | 0.95 (0.91–0.99) | 2.92E-02 | Meta |
| TRIML1 | 4q35.2 | 0.73 (0.64–0.84) | 1.68E-05 | Meta |
| RAB3C | 5q11.2 | 1.07 (1.03–1.13) | 2.46E-03 | Meta |
| PRKAA1 | 5p13.1 | 0.80 (0.77–0.83) | 4.83E-26 | Meta |
| GPX3 | 5q33.1 | 0.92 (0.89–0.95) | 1.49E-06 | Meta |
| LINC01411 | 5q35.2 | 1.05 (1.01–1.10) | 2.65E-02 | Meta |
| UNC5CL | 6p21.1 | 1.14 (1.09–1.20) | 7.22E-08 | Meta |
| SAMD5 | 6q24.3 | 0.81 (0.75–0.88) | 5.62E-07 | Meta |
| PSCA | 8q24.3 | 0.75 (0.72–0.78) | 8.20E-56 | Meta |
| ABO | 9q34.11 | 1.15 (1.11–1.19) | 2.64E-13 | Meta |
| PLCE1 | 10q23.33 | 3.60 (2.46–5.26) | 3.51E-11 | Burden Test |
| LOC101928477 | 11q22.2 | 0.95 (0.84–1.08) | 4.29E-01 | Meta |
| DYNC2H1 | 11q22.3 | 0.95 (0.91–1.00) | 3.30E-02 | Meta |
| OPCML | 11q25 | 1.19 (1.11–1.28) | 1.60E-06 | Meta |
| CCDC63 | 12q24.11 | 0.92 (0.89–0.96) | 1.80E-05 | Meta |
| CUX2 | 12q24.12 | 0.91 (0.88–0.94) | 3.20E-08 | Meta |
| DTX1 | 12q24.13 | 1.15 (1.09–1.21) | 1.20E-07 | Meta |
| GPC5 | 13q31.3 | 1.07 (1.02–1.11) | 2.31E-03 | Meta |
| UBAC2 | 13q32.3 | 1.07 (1.03–1.11) | 2.71E-04 | Meta |
| FMN1 | 15q13.3 | 1.11 (1.05–1.17) | 4.53E-04 | Meta |
| TRPM1 | 15q13.3 | 0.61 (0.50–0.74) | 5.87E-07 | Meta |
| RORA | 15q22.2 | 1.09 (1.04–1.14) | 1.83E-04 | Meta |
| SNX29 | 16p13.13 | 0.92 (0.88–0.96) | 1.83E-04 | Meta |
| HA O 1 | 20p12.3 | 0.92 (0.87–0.96) | 7.20E-04 | Meta |
| DEFB121 | 20q11.21 | 1.11 (1.07–1.15) | 8.11E-10 | Meta |
OR, odds ratio; CI, confidence interval; BT, burden test.